Reuters reports FDA has shelved its national priority voucher pilot; HHS says it is ongoing. What 22 voucher holders and nine pending reviews face now.
Last updated: November 13, 2026
Reuters reported on November 12 that FDA has quietly shelved the Commissioner’s National Priority Voucher pilot, which promised drug decisions in 1 to 2 months. HHS says the pilot is ongoing. Nine drugs still in the program are now on timelines set by career reviewers, according to Reuters.
Scope: what was reported, what FDA and HHS said on the record, what the program’s own documents promised, and what voucher holders and sponsors planning filings should do next.
What did Reuters report about the FDA priority voucher program?
Reuters reported, citing six sources and internal documents, that FDA has shelved the Commissioner’s National Priority Voucher (CNPV) pilot. No new vouchers have gone out since Commissioner Marty Makary left the agency in May, and the executive council of political appointees that ran the reviews has gone dormant, according to the report.
The story, by Patrick Wingrove and Yasmeen Abutaleb, landed Thursday, November 12. One source told Reuters that FDA leadership has told companies the agency is not moving forward with the program but is keeping applications open, and that submissions now simply do not advance. Two sources said FDA career scientists have resumed overseeing review timelines for the nine drugs still in the program.
Reuters counted 22 drugs awarded vouchers and 12 approved, five of them after Makary’s departure. For several drugs, the program sped approval by eight months or more, per the report. Rich Danker, a former HHS assistant secretary, told Reuters the initiative is “quietly being phased out.”
What did FDA and HHS say?
HHS disputes the characterization. HHS spokesperson Emily Hilliard told Reuters the pilot is ongoing and that FDA is reviewing feedback from a June public hearing to refine the framework. FDA told BioSpace that “FDA career staff continues to evaluate applications granted a CNPV” and that its “commitment to its core mission remains unchanged.”
Read those statements closely. Neither says new vouchers are coming, and neither commits to the 1 to 2 month clock. “Career staff continues to evaluate” is consistent with the Reuters account that reviews have returned to normal center processes. RBC Capital Markets told BioSpace there is no official FDA guidance on the program’s status, and that it is not clear how far the change reaches companies that already hold a voucher.
What did the CNPV program promise?
FDA announced the program on June 17, 2025. Its release said a voucher shortens review from approximately 10 to 12 months to 1 to 2 months after a sponsor’s final application submission. In exchange, sponsors had to submit the chemistry, manufacturing and controls section and draft labeling at least 60 days before the final application, and stay available for fast responses.
The mechanism was a one day multidisciplinary meeting modeled on an oncology tumor board, where the review team and senior leadership worked through the file together. FDA’s program page, last updated October 19, 2026, lists five priorities: public health crisis response, innovative breakthrough therapies, large unmet medical needs, onshoring and supply chain resilience, and affordability. It also says the approval decision “remains with the relevant product Center, using the Center’s normal processes,” with recommendations shared with a CNPV Review Council.
FDA reserved the right to extend the review if data were incomplete, pivotal results ambiguous or the review unusually complex. That clause matters now, because it gives the agency room to slow any remaining voucher review without formally ending anything.
Which drugs got vouchers and approvals?
The first nine vouchers were announced October 16, 2025. FDA’s program page links later award announcements on November 6, December 15 and December 19, 2025, and April 24, 2026, and lists 11 dated approvals through October 19, 2026. Reuters puts the approval count at 12.
| Milestone | Date | Source |
|---|---|---|
| Program announced, 1 to 2 month target | June 17, 2025 | FDA release |
| First nine vouchers (including Pergoveris, teplizumab, cytisinicline, DB-OTO, cenegermin, RMC-6236, bitopertin, ketamine and Augmentin XR manufacturing) | October 16, 2025 | FDA release |
| First approval (domestic antibiotic manufacturing) | December 9, 2025 | FDA program page |
| Higher dose semaglutide approval | March 19, 2026 | FDA program page |
| First new molecular entity approval | April 1, 2026 | FDA program page |
| First gene therapy for genetic hearing loss | April 23, 2026 | FDA program page |
| Makary leaves FDA; no new vouchers since | May 2026 | Reuters |
| Public hearing on the program | June 4, 2026 | FDA program page |
| First oral PCSK9 inhibitor approval | July 17, 2026 | FDA program page |
| Metastatic pancreatic cancer targeted therapy approval | August 26, 2026 | FDA program page |
| Rectal cancer immunotherapy approval (latest listed) | October 19, 2026 | FDA program page |
| Reuters reports program shelved; HHS says ongoing | November 12, 2026 | Reuters, HHS |
Reuters reported that Merck’s cholesterol pill Lipfendra and Revolution Medicines’ pancreatic cancer drug Rasonque were approved after Makary left without being vetted by the council, and that Rasonque came through on a typical breakthrough oncology timeline. That detail is the tell: late voucher approvals already looked like ordinary priority reviews.
What happens to the nine drugs still holding vouchers?
The short answer: plan as if the clock is the standard PDUFA clock. Two sources told Reuters that career scientists now set the timelines for the nine remaining drugs, and FDA’s own statement says career staff continue to evaluate CNPV applications.
The clearest case is Merck KGaA’s Pergoveris, one of the first nine voucher drugs and one tied to a drug pricing agreement. Reuters reported it remains unapproved three months after FDA accepted its final application, following an eight month rolling review. Under the original promise, it would have had a decision by now.
Psychedelic sponsors are also exposed. BioSpace notes that Compass Pathways (COMP360) and the Usona Institute (PSIL201) have submitted depression applications and both hold vouchers. If the vouchers no longer buy speed, their timelines default to whatever review designation each application already carries.
Why does this matter beyond the voucher holders?
It shows how much of FDA’s recent speed depended on people rather than rules. The CNPV was a pilot run by political leadership, not a statutory program like PDUFA or the rare pediatric priority review voucher, so it could stall without a rule change, a notice or a vote. Reuters reports the agency has had no commissioner since May.
The leadership question is on the calendar. BioSpace reports a committee vote on commissioner nominee Heidi Overton is scheduled for November 18, with analysts at William Blair flagging uncertainty over whether she has a majority. A confirmed commissioner could revive, rebrand or formally end the program. Until then, sponsors should treat any review promise that is not written into PDUFA goals as soft.
There is also a staffing angle. Our nightly coverage reported a decline of 1,343 CBER and CDER employees between September 2024 and September 2026, per FDA hiring data cited by trade press. A one day, all hands review format is hard to run with thinner benches.
What should sponsors do now? Our checklist
This is our framework for regulatory and finance teams, not FDA guidance.
- Reset the model. If a forecast assumes a 1 to 2 month CNPV decision, move it to the applicable PDUFA goal (6 months for priority, 10 months for standard, counted from the 60 day filing date for new molecular entities) until FDA says otherwise in writing.
- Ask the division directly. Request written confirmation of the review timeline and whether a goal date has been set. Get it in meeting minutes.
- Keep the CMC advantage. The early CMC and labeling submission the program required still shortens real review time. Do not unwind it.
- Check disclosure. Public companies that cited a voucher timeline in filings or guidance should review whether an update is needed.
- Do not lean on undesignated vouchers. A voucher awarded but not yet redeemed may carry little practical value until the program’s status is formalized.
- Watch the commissioner vote. The November 18 committee vote is the first real signal on whether the program has a future.
What to watch next
- The Senate committee vote on Heidi Overton, scheduled for November 18, per BioSpace.
- Any FDA written notice to voucher holders or an update to the CNPV program page, which still describes an active pilot.
- The Pergoveris decision, which will show how long a voucher review now takes.
- Decisions on the psychedelic applications from Compass Pathways and Usona.
- Whether FDA publishes conclusions from the June 4, 2026 public hearing that HHS says it is reviewing.
FAQ
What is the Commissioner’s National Priority Voucher?
A pilot FDA launched in June 2025 that gave selected drugs a review target of 1 to 2 months after the final application, using a one day team review modeled on an oncology tumor board. Vouchers were nontransferable.
Has FDA officially ended the CNPV program?
No. Reuters reported it has been shelved, citing six sources and internal documents. HHS says the pilot is ongoing, and FDA says career staff continue to evaluate voucher applications. No formal termination notice has been published.
How many CNPV vouchers were awarded?
Reuters reported 22 drugs received vouchers. FDA’s program page links award announcements from October 2025 through April 2026 but does not give a single total.
How many CNPV drugs have been approved?
Reuters counted 12 approvals, five after Commissioner Makary left in May 2026. FDA’s program page lists 11 dated approvals through October 19, 2026.
What happens to pending voucher applications?
According to two Reuters sources, career scientists now oversee timelines for the nine drugs still in the program. Sponsors should assume standard PDUFA timing unless their review division confirms otherwise in writing.
How is the CNPV different from a priority review voucher?
Priority review vouchers come from statute, are transferable and cut a review to the six month priority clock. The CNPV was an administrative pilot, nontransferable, and promised a much faster 1 to 2 month target.
Why did the program stall?
Reuters links it to leadership departures: Makary left in May, and council members including former acting drug center director Tracy Beth Hoeg and former biologics chief Vinay Prasad also left. The program depended on that council.
Did the program actually speed approvals?
Yes for some. Reuters reported several drugs were approved eight months or more faster. Later approvals, including Rasonque, came on more typical timelines, per Reuters.
Who is the FDA commissioner now?
FDA has been without a commissioner since May, per Reuters. Heidi Overton is the nominee, with a committee vote scheduled for November 18, according to BioSpace.
Should sponsors still apply for a voucher?
Applications reportedly remain open but do not advance. Sponsors can file, but should not build any plan around a voucher until FDA clarifies the program in writing.
Sources
- FDA, “FDA to Issue New Commissioner’s National Priority Vouchers to Companies Supporting U.S. National Interests,” June 17, 2025 (primary).
- FDA, “FDA Awards First Ever National Priority Vouchers to Nine Sponsors,” October 16, 2025 (primary).
- FDA, Commissioner’s National Priority Voucher (CNPV) Pilot Program page, content current as of October 19, 2026 (primary).
- Reuters, Patrick Wingrove and Yasmeen Abutaleb, “Exclusive: US FDA shelves commissioner’s voucher program for speedy drug reviews, sources say,” November 12, 2026 (attributed: sources, voucher and approval counts, Pergoveris, Danker and HHS comments).
- BioSpace, Heather McKenzie, November 12, 2026 (attributed: FDA statement, RBC comment, Overton vote date, psychedelic applications).
- Pharmacy Times and PharmTech coverage of the Reuters report, November 12, 2026 (attributed).
Related coverage
- FDA approval pathways and designations explained
- FDA accelerated approval: confirmatory trial rules explained
- Rasonque wins the first broad RAS targeted approval in pancreatic cancer
- Heidi Overton expected to be nominated to lead FDA
- Friday’s daily: enGene, Vir’s offering and FDA staffing
- BioMed Nexus company directory
Get the daily briefing that tracks FDA policy shifts before they hit your timeline: subscribe to BioMed Nexus.
